Comparison · Precursor vs active metabolite~7 min readUpdated 12 May 2026

7-Hydroxymitragynine vs Mitragynine

Q: Does kratom convert to 7-OH in your body?

Yes. The hepatic enzyme CYP3A4 converts mitragynine to 7-hydroxymitragynine in vivo. When researchers block that conversion in animal models, the analgesic effect of ingested mitragynine largely disappears — even at doses that would normally produce strong antinociception (Kruegel 2019). Most of what you feel as 'kratom's opioid effect' is actually 7-OH that your liver manufactured from the mitragynine in the leaf.

Q: Why do product labels focus on mitragynine content?

Because mitragynine is abundant in leaf (50–80 mg per 5 g serving) and easy to measure. A label showing '120 mg mitragynine' looks impressive. But mitragynine is the precursor, not the active opioid — and only a fraction of it converts to 7-OH via CYP3A4. Conversely, a product advertising a high 7-OH percentage is signalling that it's a concentrate or semi-synthetic extract, not natural leaf. Both numbers are informative; neither tells you how much 7-OH actually reaches your receptor.

Q: Is mitragynine safer than 7-OH?

On its own, mitragynine appears to have lower abuse liability than 7-OH — rats don't reliably self-administer it, while they self-administer 7-OH at morphine-comparable rates (Hemby 2019). Mitragynine also has a broader pharmacological profile (adrenergic, serotonergic targets) that contributes to stimulant effects at low doses. But the safety distinction is partly an illusion: when you take mitragynine in leaf form, your liver converts it to 7-OH, so you're still getting 7-OH exposure — just metered more slowly by CYP3A4.

Q: Can grapefruit juice or medications change how much 7-OH I get from kratom?

Yes. Grapefruit juice is a well-known CYP3A4 inhibitor. So are ketoconazole (antifungal), ritonavir (HIV), clarithromycin (antibiotic), and several other common medications. Inhibiting CYP3A4 raises the amount of 7-OH your liver produces from mitragynine, potentially increasing both the opioid effect and the side-effect risk of a standard kratom dose. CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) have the opposite effect — less 7-OH output, weaker opioid effect. This inter-individual CYP variation is one reason 'the same dose' can produce wildly different effects between people.

Mitragynine is the alkaloid kratom has the most of. 7-OH is the alkaloid that does the most. Your liver converts one into the other — and that conversion step is the key to everything else on this page.

Table 01 · Mitragynine vs. 7-Hydroxymitragynine08 factors

Factor	Mitragynine	7-Hydroxymitragynine
Role	Most abundant kratom alkaloid (~66%)	Active metabolite — does the opioid work
Present in leaf	~50–80 mg per 5 g serving	<0.15 mg per 5 g serving (trace)
Mu-opioid affinity	Baseline (1×)	~46× mitragynine, ~13× morphine
Becomes opioid-active via	CYP3A4 conversion in the liver → 7-OH	Already active — no conversion needed
Low-dose experience	Coffee-like focus and energy	Opioid warmth and sedation from the start
Abuse liability (rats)	Not reliably self-administered	Self-administered at morphine-comparable rates
Drug interactions	CYP3A4 inhibitors raise 7-OH output	CYP3A4 inhibitors slow clearance
Why product labels show it	Abundant — easy to measure, looks impressive	Trace in leaf — high % signals concentrate, not leaf

The conversion step that explains everything

Mitragynine is converted to 7-hydroxymitragynine in your liver by the enzyme CYP3A4 (Kruegel 2019; Kamble 2020). When researchers block that conversion in animal models, the analgesic effect of ingested mitragynine largely disappears — even at doses that would normally produce strong antinociception. The clean interpretation: mitragynine is not doing the opioid work. 7-OH is. Mitragynine is the raw material; your liver is the factory; 7-OH is the product.

This is the foundation of the entire “natural vs. concentrated” regulatory argument. A kratom leaf product hands the body a large pool of mitragynine and lets CYP3A4 meter out 7-OH at its own rate. A concentrated 7-OH tablet hands the body pre-formed 7-OH directly, bypassing the rate limit. Same alkaloid at the receptor. Different delivery speed. Different dependence trajectory.

What the conversion step feels like in practice

Low-dose kratom leaf — 2 to 4 grams — feels stimulating: energy, focus, mild sociability. This is mitragynine’s direct pharmacology (adrenergic, serotonergic, dopaminergic activity) before CYP3A4 has produced enough 7-OH for the opioid character to show up. As dose climbs, conversion accelerates, and the opioid warmth, sedation, and analgesia emerge — that’s 7-OH accumulating at the receptor.

A concentrated 7-OH product skips the wait. The opioid effect is immediate because you’re delivering 7-OH directly. No stimulant ramp. No coffee-like focus phase. The subjective profile sits closer to a pharmaceutical opioid from the first milligram.

Why your CYP3A4 activity matters more than the dose

CYP3A4 expression varies dramatically between individuals — genetic polymorphism, liver health, diet, and concurrent medications all shift the conversion rate. Practically, this means:

CYP3A4 inhibitors (grapefruit juice, ketoconazole, ritonavir, clarithromycin) raise the amount of 7-OH your liver produces from mitragynine. The same kratom dose hits harder.
CYP3A4 inducers(rifampin, carbamazepine, St. John’s wort) lower 7-OH output. The same dose feels weaker.
Genetic slow metabolisersproduce less 7-OH from a given dose of leaf. Genetic fast metabolisers produce more. This is one reason “the same dose” can produce wildly different effects between two people, and why the dosage guide recommends building a personal baseline over five to ten sessions rather than trusting a number.

For pre-formed 7-OH products (tablets, shots), CYP3A4 variation matters less for production but still matters for clearance — the enzyme helps eliminate 7-OH from the body (Kamble 2020). Inhibitors can extend the duration; inducers can shorten it.

What product labels are actually telling you

Kratom product labels typically show mitragynine content in milligrams — “120 mg mitragynine per serving” — because mitragynine is abundant and easy to measure. But mitragynine is the precursor, not the active opioid. That number tells you how much raw material your liver has to work with. It does not tell you how much 7-OH reaches the receptor.

Conversely, a product advertising a high 7-OH percentage or a specific 7-OH milligram content is signalling that it’s a concentrate or semi-synthetic extract — not natural leaf. This is the distinction KCPA states use to draw the legal line: 7-OH above 1–2% of total alkaloids = regulated or banned; below that threshold = permitted as leaf.

The precursor is largely inert as a reinforcer. The active metabolite is not. That asymmetry is the pharmacological basis for every state law that distinguishes leaf from concentrate.

Dependence risk is not symmetric

Rats reliably self-administer 7-OH at rates comparable to morphine but do not reliably self-administer mitragynine (Hemby 2019). This mirrors the receptor data: the precursor is largely inert as a reinforcer; the active metabolite is not. Physical dependence on a concentrated 7-OH product is expected to develop faster than dependence on the same total alkaloid content delivered as leaf mitragynine — because the rate-limiting CYP3A4 conversion step is gone. Full timeline and management on the withdrawal page.

Common questions

04 answers

01Does kratom convert to 7-OH in your body?

Yes. The hepatic enzyme CYP3A4 converts mitragynine to 7-hydroxymitragynine in vivo. When researchers block that conversion in animal models, the analgesic effect of ingested mitragynine largely disappears — even at doses that would normally produce strong antinociception (Kruegel 2019). Most of what you feel as 'kratom's opioid effect' is actually 7-OH that your liver manufactured from the mitragynine in the leaf.

02Why do product labels focus on mitragynine content?

Because mitragynine is abundant in leaf (50–80 mg per 5 g serving) and easy to measure. A label showing '120 mg mitragynine' looks impressive. But mitragynine is the precursor, not the active opioid — and only a fraction of it converts to 7-OH via CYP3A4. Conversely, a product advertising a high 7-OH percentage is signalling that it's a concentrate or semi-synthetic extract, not natural leaf. Both numbers are informative; neither tells you how much 7-OH actually reaches your receptor.

03Is mitragynine safer than 7-OH?

On its own, mitragynine appears to have lower abuse liability than 7-OH — rats don't reliably self-administer it, while they self-administer 7-OH at morphine-comparable rates (Hemby 2019). Mitragynine also has a broader pharmacological profile (adrenergic, serotonergic targets) that contributes to stimulant effects at low doses. But the safety distinction is partly an illusion: when you take mitragynine in leaf form, your liver converts it to 7-OH, so you're still getting 7-OH exposure — just metered more slowly by CYP3A4.

04Can grapefruit juice or medications change how much 7-OH I get from kratom?

Yes. Grapefruit juice is a well-known CYP3A4 inhibitor. So are ketoconazole (antifungal), ritonavir (HIV), clarithromycin (antibiotic), and several other common medications. Inhibiting CYP3A4 raises the amount of 7-OH your liver produces from mitragynine, potentially increasing both the opioid effect and the side-effect risk of a standard kratom dose. CYP3A4 inducers (rifampin, carbamazepine, St. John's wort) have the opposite effect — less 7-OH output, weaker opioid effect. This inter-individual CYP variation is one reason 'the same dose' can produce wildly different effects between people.